Seeking Alpha
14 Jul 2026, 17:40 UTC · 14w ago
Verdict
Headline takes no side. We score SPRO +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
What the story claims
3 claims · scored −1 bearish … +1 bullish
Spero Therapeutics secured a $105M royalty deal and FDA approval for Utebzi, providing non-dilutive funding for the development of SP001.
So whatSignificant non-dilutive capital drastically reduces the risk of shareholder dilution and provides a critical cash runway for R&D.
More positive than 99% of claims this week
The company is developing SP001, a third-generation anti-CD40L antibody targeting IgG4-RD and Sjögren's disease.
Continue reading
5 related stories
More positive than 88% of claims this week
Phase 2 clinical trials for SP001 are planned to begin in 2027.
More negative than 67% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Initiated with a Buy rating following FDA approval and a $105M royalty deal that funds development without shareholder dilution.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
19h ago
−44.0%
Price is moving against the score
$1.22 vs $2.18 close before publication (Jul 13) · not market-adjusted
SPRO chart →
